Compare TBPH & CRTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | CRTO |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.9M | 806.9M |
| IPO Year | 2013 | 2013 |
| Metric | TBPH | CRTO |
|---|---|---|
| Price | $16.08 | $18.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $18.40 | ★ $34.00 |
| AVG Volume (30 Days) | 289.3K | ★ 367.1K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 279.13 | 38.95 |
| EPS | N/A | ★ 0.15 |
| Revenue | $15,386,000.00 | ★ $2,296,692,000.00 |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | N/A | $5.54 |
| P/E Ratio | ★ N/A | $122.23 |
| Revenue Growth | N/A | ★ 27.65 |
| 52 Week Low | $9.98 | $15.58 |
| 52 Week High | $21.03 | $27.32 |
| Indicator | TBPH | CRTO |
|---|---|---|
| Relative Strength Index (RSI) | 40.51 | 56.18 |
| Support Level | $13.41 | $18.04 |
| Resistance Level | $17.21 | $19.98 |
| Average True Range (ATR) | 0.34 | 0.60 |
| MACD | -0.06 | 0.23 |
| Stochastic Oscillator | 4.84 | 82.82 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.